Latest News for: syk

Edit

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Rigel Pharmaceuticals Leads ...

Business Wire 08 Jan 2026
Global SYK Inhibitor Market Growth 2020-2024. 13% CAGR Approved SYK Inhibitor Drugs.
Edit

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Rigel Pharmaceuticals Leads With Fostamatinib and Hutchmed's Sovleplenib Emerges as Late-Stage Breakthrough Candidate for ITP - ResearchAndMarkets.com

Pharmiweb 07 Jan 2026
DUBLIN--(BUSINESS WIRE)--The "SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook 2030" report has been added to ResearchAndMarkets.com's offering ... Global SYK Inhibitor Market Growth 2020-2024. 13% CAGR Approved SYK Inhibitor Drugs.
Edit

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Ongoing Global Trials ...

Nasdaq Globe Newswire 06 Jan 2026
The SYK inhibitor market is poised for rapid growth, driven by increased interest in addressing unmet needs in autoimmune diseases, ...
Edit

Stryker (SYK) Stock Trades Up, Here Is Why

The Call 06 Jan 2026
What Happened?. Shares of medical technology company Stryker (NYSE. SYK) jumped 4.1% in the afternoon session after analyst firm Raymond James upgraded the stock to "Outperform" from "Market Perform" and set a $418 price target ... More News. View More ... .
Edit

SYK Inhibitors Pipeline Outlook Report 2025: DelveInsight Analyzes Key R&D Progressions Powering Next-Generation Therapies

GetNews 25 Nov 2025
DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape.
Edit

Why Stryker (SYK) Shares Are Trading Lower Today

The Call 31 Oct 2025
What Happened?. Shares of medical technology company Stryker (NYSE. SYK) fell 2.9% in the afternoon session after it reported underwhelming earnings ... The company's operating margin contracted to 18.7% from 19.7% in the same period last year ... More News ... .
Edit

Stryker (NYSE:SYK) Posts Q3 Sales In Line With Estimates

The Call 30 Oct 2025
SYK) met Wall Streets revenue expectations in Q3 CY2025, with sales up 10.2% year on year to $6.06 billion ... Stryker (SYK) Q3 CY2025 Highlights. ... SYK) develops and manufactures advanced medical devices ...
Edit

Stryker (SYK) Reports Q3: Everything You Need To Know Ahead Of Earnings

The Call 29 Oct 2025
Medical technology company Stryker (NYSE. SYK) will be reporting results this Thursday afternoon. Here’s what investors should know ... Is Stryker a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members ... More News ... .
  • 1

Article Search

tools
×
×
×
×